Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
HIV rapidly develops resistance to gene-editing cure technology

In a setback for a novel approach to curing HIV, researchers involved in a technique that uses enzymes to remove viral genes from the DNA of infected

Published
17 May 2016
By
Gus Cairns
South Africa takes bold step to provide HIV treatment for all

The Government of South Africa has announced a major policy shift that will move the world faster towards the global 90–90–90 treatment target. On 10 May 2016, the South African Minister of Health, Aaron Motsoaledi, announced in his Health Budget Vote Speech to the Parliament of South Africa that the country will implement a new evidence-based policy of offering HIV treatment to all people living with HIV by September 2016.

Published
16 May 2016
From
UNAIDS
South Africa moves to ‘test and treat’

Treasury has allocated an extra R1-billion to finance this “universal test and treat” (UTT) programme, Health Minister Aaron Motsoaledi announced during his budget speech in Parliament today.

Published
16 May 2016
From
Health-e News
South Africa to adopt WHO’s ‘test and treat’ HIV guidelines

SA WILL adopt the World Health Organization’s new "test and treat" guidelines for HIV patients in September, enabling people to start treatment as soon as they are diagnosed instead of having to wait until their immune systems weaken, Health Minister Aaron Motsoaledi announced on Tuesday.

Published
10 May 2016
From
Business Day
Spirituality May Help HIV Patients Survive Longer

Over 17 years, researchers followed HIV-positive men and women who were already in the mid-stage of their disease by the time the study began. They found that people who engaged in spiritual practices and thinking had a greater rate of survival than people who did not—two to four times greater, in fact.

Published
09 May 2016
From
The Atlantic
A simple ask in 2016: the UN goal of universal HIV treatment

Last week, the working draft for 2016 UN Political Declaration on HIV/AIDS was released with only a few days for comments. Called the Zero draft, like previous statements produced every five years, it is a list of observations, comments and goals. But using the UN Statement as a platform of human rights has become disconnected from the scientific and medical advances in HIV over the last five years. The bulk of the draft document could have been written at any time during the epidemic, certainly most of it could have been written in 2011. There is only one reference to dramatic changes in the WHO 2015 guidelines and only two references to PrEP.

Published
28 April 2016
From
i-Base
Newly Diagnosed HIV+ Men Are Embracing Treatment More Than Ever Before

Gay and bisexual men who are newly diagnosed with HIV change their behaviour to reduce the chance of onward transmission, according to the results of a long-running Australian study released today. It found that more newly diagnosed men are adopting treatment as prevention (TasP) than ever before.

Published
26 April 2016
From
Star Observer
First in, best health: treat HIV now

It may be over 30 years since HIV hit the world, but it’s only recently that a study finally revealed the sooner a person diagnosed with HIV begins taking antiretroviral medication, the better it is for their long-term health outcomes. In light of this, the Victorian AIDS Council (VAC) and Living Positive Victoria (LPV) have teamed up to launch their first ever social marketing campaign dedicated solely to early treatment: Treat HIV Now.

Published
26 April 2016
From
Star Observer
European Commission Grants Marketing Authorization for Gilead’s Fixed-Dose Combination Descovy® (Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV

Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for two doses of Descovy® (emtricitabine and tenofovir alafenamide 200/10 mg and 200/25 mg; F/TAF), a fixed-dose combination for the treatment of HIV-1 infection. Descovy is Gilead’s second TAF-based therapy to receive marketing authorization in the European Union.

Published
25 April 2016
From
Gilead press release
ViiV Healthcare, Medicines Patent Pool Extend Licence for Dolutegravir to All Lower Middle-Income Countries

The Medicines Patent Pool (MPP) and ViiV Healthcare announced an extension of their current licensing agreement today to increase access to dolutegravir (DTG), a promising new antiretroviral, to cover all remaining lower middle-income countries. The amendment to the 2014 licence specifically allows generic medicine distribution in four countries with patents - Armenia, Moldova, Morocco and Ukraine - that were not covered in the initial agreement. MPP sub-licensees can now sell in countries that are home to 94% of people living with HIV in the developing world.

Published
25 April 2016
From
ViiV Healthcare press release

Filter by country